Skip to content
Catalyst

knowcompoundsrosuvastatin

Specimen compound organic compoundPlate I

Rosuvastatin

Nested hairline contours trace the electron density of one computed shape of rosuvastatin, teal at the edge warming to amber over the atoms.
fig. 1Rosuvastatin · electron density · PubChem CID 446157, computed 3D conformer
Formula
C22H28FN3O6S
Molar mass
481.546 g/mol
PubChem CID
446157
InChIKey
BPRHUIZQVSMCRT-VEUZHWNKSA-N

↓ lowered

01 · the evidence, ordered

What the evidence says

Fig. 2 Rosuvastatin CHEBI:38545 1 endpoint its finding
×1.60
Labels
CompoundInspector

Rosuvastatin

36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

02 · findings

What rosuvastatin moved, and by how much

  • MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  1. Diastolic blood pressureMoved: lowersEffect, as reportedMD−2.12[−3.72 to −0.52]Evidence: ModeratePaper: PMID 348183502021
    Who
    Patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents (an ARB, or an ARB plus a calcium channel blocker), compared with the same antihypertensive background alone
    Dose studied
    rosuvastatin 20 mg/day

    The patients treated with rosuvastatin in addition to antihypertensives had a significantly lower DBP (MD = −2.12 mmHg; 95% CI = −3.72 to −0.52; Pfixed-effects model = 0.009; I 2 = 0%, Pheterogeneity = 0.97) than the patients treated with antihypertensives alone.”

    Quoted verbatim from Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.meta-analysis · 8 weeksPermalink

No dose is advised.

  • MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 3Rosuvastatin · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O

04 · figures · 1 plate

Plates

  • A dial of hairlines, each a peak of rosuvastatin's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 4Rosuvastatin · MS2 [M+H]+ LC-ESI-ITFT positive · MassBank MSBNK-Eawag-EA280206 (Stravs M, CC BY)

05 · the record

Sources

788

papers screened for rosuvastatin

admitted
1
read and discarded
157
not read yet
630

The screening record, every paper and why

Documented interactions
None reported

Sources cited

1 paper · 1 finding

Show every paper citedHide the papers cited